FilingReader Intelligence
Haisco Pharmaceutical gets FDA approval for clinical trial
July 15, 2025 at 05:11 PM UTC•By FilingReader AI
Haisco Pharmaceutical Group received a "Study May Proceed Letter" from the U.S. FDA, approving its clinical trial application for HSK47388 tablets submitted in May 2025.
HSK47388 is an orally administered drug designed for autoimmune diseases, showing promising preclinical results. A domestic application was also accepted in May 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002653•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Haisco Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime